Barely Significant
← all phrases

“an increasing trend”

63,972 sentences · 63,972 papers · 107,686 search hits before verification · confirmed specimen

Sighted at

p<0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Since after cytokine treatment significant differences are not appreciable between cells, whether pre-treated or not, but an increasing trend of p62 mRNA and protein under cinnamon pre-treatment is observable, we could speculate that p62 might be mainly engaged in these regulatory pathways rather than only in the autophagic machinery.
In the relative pressure P/P0 range of 0.4 to 1.0, the adsorption of molecular sieve showed an increasing trend, resulting in the adsorption-desorption isotherm not overlapping and the desorption isotherm being above the adsorption isotherm, thus making the nitrogen adsorption-desorption curve appear a clear hysteresis loop, which indicates that the molecular sieve has a certain mesoporous structure, and the hysteresis loop may be due to the occurrence of the molecular sieve mesopore channel This indicates that the molecular sieve has a mesoporous structure, and the hysteresis loop may be caused by capillary aggregation in the pore channels of the molecular sieve [ 30 ].
Effect of Sr on Intracellular Ca 2+ Level in Rumen Epithelial Cells The Ca 2+ staining fluorescence value was significantly increased in the 20 mmol/L Sr treatment group compared to the 0 mmol/L Sr group ( p < 0.05) ( Figure 1 D), suggesting that the intracellular Ca 2+ level had an increasing trend with increasing Sr doses. 2.3.
The temperature of the shear area will decrease with the increase of the cooling hydraulic pressure, weakening the softening effect of the material and slowing down the rate of instability of the shear surface material due to adiabatic shearing, that is, the angle between the inside of the serrated segment is increased and the adiabatic shear angle is reduced, resulting in an increasing trend in chip thickness.
However, tocilizumab treatment at 232 μg/mL produced significant increases in high mobility group box 1 protein (HMGB1) release at day 3 of treatment, and tocilizumab treatment (232 and 725 μg/mL) showed an increasing trend in HMGB1 release at day 10 of treatment ( Figure 1 B,C).